Additional information
| Active substance | Trastuzumab |
|---|---|
| Acne | No |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | No |
| Aromatization | No |
| Lab Test | HER2 testing (immunohistochemistry or fluorescence in situ hybridization) |
| Also known as | rhuMAb HER2 |
| WAREHOUSE | International Warehouse 2 |
| Blood pressure | Can cause hypertension |
| Trade name | Herceptin |
| Storage conditions | Store refrigerated at 2-8В°C (36-46В°F) |
| Chemical name | Trastuzumab |
| Formula | C6484H9996N1720O2014S44 |
| Substance class | Monoclonal antibody |
| Main action | HER2/neu receptor antagonist |
| Half-life | Approximately 28 days |
| Dosage (medical) | Typically 4 mg/kg as a loading dose followed by 2 mg/kg weekly or 6 mg/kg every three weeks |
| Dosage (sports) | Not applicable |
| Effects | Reduction in tumor growth, improved survival in breast cancer patients |
| Side effects | Fever, nausea, vomiting, infusion reactions, cardiotoxicity |
| Use in sports | None |
| Manufacturer | Roche |
Reviews
There are no reviews yet.